{"DataElement":{"publicId":"4669132","version":"1","preferredName":"Melanoma Treatment Prior Regimen Type","preferredDefinition":"information related to the type of prior treatment regimen administered to a patient with melanoma.","longName":"MEL_TX_PRI_RGM_TP","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"4669127","version":"1","preferredName":"Melanoma Treatment Prior Regimen","preferredDefinition":"information related to the prior treatment regimen for melanoma.","longName":"MEL_TX_PRIOR_RGM","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"4669125","version":"1","preferredName":"Melanoma Therapy","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C3224:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CCB1F22-2BFA-2758-E050-BB89AD43676F","latestVersionIndicator":"Yes","beginDate":"2015-01-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207592","version":"1","preferredName":"Prior Regimen","preferredDefinition":"Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"C25629:C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2971-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CCB1F22-2C08-2758-E050-BB89AD43676F","latestVersionIndicator":"Yes","beginDate":"2015-01-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4669131","version":"1","preferredName":"Melanoma Treatment Prior Regimen Type","preferredDefinition":"information related to the type of prior treatment regimen administered to a patient with melanoma.","longName":"MEL_TX_PRI_RGM_TP","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dacarbazine","valueDescription":"Dacarbazine","ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C2C-2758-E050-BB89AD43676F","beginDate":"2015-01-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Dabrafenib","valueDescription":"Dabrafenib","ValueMeaning":{"publicId":"4539014","version":"1","preferredName":"Dabrafenib","longName":"4539014","preferredDefinition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib","conceptCode":"C82386","definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"059E8F71-D4FF-7062-E050-BB89AD435032","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C36-2758-E050-BB89AD43676F","beginDate":"2015-01-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Adjuvant Interferon - alfa","valueDescription":"Adjuvant Interferon - alfa","ValueMeaning":{"publicId":"4573833","version":"1","preferredName":"Adjuvant Interferon - alfa","longName":"4573833v1.00","preferredDefinition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself._A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Interferon Alfa-N1","conceptCode":"C2220","definition":"A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071FB1D4-DD43-3C96-E050-BB89AD435506","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C40-2758-E050-BB89AD43676F","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Adjuvant Pegylated Interferon - alfa","valueDescription":"Adjuvant Pegylated Interferon - alfa","ValueMeaning":{"publicId":"4573832","version":"1","preferredName":"Adjuvant Pegylated Interferon - alfa","longName":"4573832v1.00","preferredDefinition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself._A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pegylated Interferon Alfa","conceptCode":"C2491","definition":"A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071FB1D4-DD20-3C96-E050-BB89AD435506","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C4A-2758-E050-BB89AD43676F","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Interleukin-2","valueDescription":"Interleukin-2","ValueMeaning":{"publicId":"2578198","version":"1","preferredName":"Interleukin-2","longName":"2578198","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE83-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C54-2758-E050-BB89AD43676F","beginDate":"2004-02-24","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C5E-2758-E050-BB89AD43676F","beginDate":"2002-02-11","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"PD1/PDL1 inhibitor","valueDescription":"PD1/PDL1 inhibitor","ValueMeaning":{"publicId":"4573831","version":"1","preferredName":"PD1/PDL1 inhibitor","longName":"4573831v1.00","preferredDefinition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system._An agent designed to interfere with the activity of programmed death ligand 1 (PD-L1; CD274), a ligand for the receptor programmed cell death protein 1 (PD-1; PD1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PD1 Inhibitor","conceptCode":"C124946","definition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"PD-L1 Inhibitor","conceptCode":"C191689","definition":"An agent designed to interfere with the activity of programmed death ligand 1 (PD-L1; CD274), a ligand for the receptor programmed cell death protein 1 (PD-1; PD1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071FB1D4-DCC7-3C96-E050-BB89AD435506","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C68-2758-E050-BB89AD43676F","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Temozolomide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C72-2758-E050-BB89AD43676F","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"},{"value":"Vemurafenib","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCB1F22-2C7C-2758-E050-BB89AD43676F","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ONEDATA","dateModified":"2015-01-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CCB1F22-2C19-2758-E050-BB89AD43676F","latestVersionIndicator":"Yes","beginDate":"2015-01-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ROUILLAS","dateModified":"2015-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior Therapy","type":"Preferred Question Text","description":"Prior Therapy","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CCB1F22-2C86-2758-E050-BB89AD43676F","latestVersionIndicator":"Yes","beginDate":"2015-01-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-16","modifiedBy":"ROUILLAS","dateModified":"2015-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}